مینین دفار			DT07 Ree'd PCT/PTO 1 0 FEB 2005				
FG PTO-1390 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE (Rev. 12-2001)			Attorney's Docket Number				
TF	RANSMITTAL LETTER 1	JAB1721USPCT U.S. Application No. (if known, see 37 CFR 1.5)					
DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371 10/524197							
	ernational Application No.	International Filing Date	Priority Date Claimed				
	T/EP03/50374 e of Invention	August 12, 2003	August 12, 2002				
		OXAZOLINE DERIVATIVES AND TH	IEIR USE AS ANTI-DEPRESSANTS				
Jos	plicant(s) for DO/EO/US e Ignacio Andres-Gil, Jose Manue tonius Adrianus hendrikus Petrus I		rez Escobar, Margaretha Henrica Maria Bakker				
App	plicant herewith submits to the United	States Designated/Elected Office (DO/EO/U	US) the following items and other information:				
1.	1. This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.						
2.	☐ This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.						
3.	☐ This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.						
4.	☐ The US has been elected (Article 31).						
5.	 ☑ A copy of the International Application as filed (35 U.S.C. 371(c)(2)) a. ☑ is attached hereto (required only if not communicated by the International Bureau), as well as the Published Application No. WO 2004/016621 A1 b. ☐ has been communicated by the International Bureau. c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US). 						
6.	 ☐ An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). a. ☐ is attached hereto. b. ☐ has been previously submitted under 35 U.S.C. 154(d)(4). 						
7.	 ☑ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) a. ☐ are attached hereto (required only if not communicated by the International Bureau). b. ☐ have been communicated by the International Bureau. c. ☐ have not been made; however, the time limit for making such amendments has NOT expired. d. ☒ have not been made and will not be made. 						
8.	☐ An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)).						
9.	An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).						
10.	An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).						
11.	Items 11 to 20 below concern document(s) or information included: 11. An Information Disclosure Statement under 37 CFR 1.97 and 1.98.						
12.	2. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.						
13.	3. A FIRST preliminary amendment.						
14.	14. An Application Data sheet under 37 CFR 1.76						
15.	15. A substitute specification.						
16.	16. A power of attorney						
17.	17. A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825.						

20. Other items or information: Express Mail Certificate

page 1 of 2 (REV. 1-98)

18. A second copy of the published international application under 35 U.S.C. 154(d)(4).

19. A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).

accompanied by an appropriate cover sheet (57 C) K	7.20, 3.31). 340.00 pci pi	operty .	_			
TOTA	L FEES ENCLOSED	=	\$1000.00			
			Amount to be			
			refunded:	\$		
			charged:	\$1000.		
 a. A check in the amount of \$ to b. Please charge my Deposit Account No. above fees. A duplicate copy of this sheet is enc 	10-0750/JAB1721USP		n the amount of	\$1000.0		
c. The Commissioner is hereby authorized to charge any additional fees which may be required, or cr overpayment to Deposit Account No. 10-0750/JAB1721USPCT/HBW. A duplicate copy of this						
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to 1.137 (a) or (b)) must be filed and granted to restore the application to pending status.						
SEND ALL CORRESPONDENCE TO:	Hal	Bung (Doodrou			
Philip S. Johnson, Esq	Signatu	re				
Johnson & Johnson						
One Johnson & Johnson Plaza	Hal B. V	Woodrow				
New Brunswick, NJ 08933-7003 USA	Name					
	32,501					
		ition Numb	er			
Dated: February 10, 2005						

DT05 REPCT/PTO 1 0 FEB 2005

Docket No. JAB1721USPCT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:

Jose Ignacio Andres-Gil et al.

For:

C-SUBSTITUTED TRICYCLIC ISOXAZOLINE DERIVATIVES AND THEIR

USE AS ANTI-DEPRESSANTS

Express Mail Certificate

"Express Mail" mailing number:

EV 488942325 US

Date of Deposit:

February 10, 2005

I hereby certify that this entry into the National Phase pursuant to 35 USC 371 contains complete application:

\boxtimes	Express Mail Certificate	(1 page)
\boxtimes	Return Receipt Postcard	(1 page)
\boxtimes	PCT FORM 1390 Transmittal	(2 pages & 2 copies of same)
	Copy of International Application as filed	(55 pages)
\boxtimes	Power of Attorney	(5 pages)
\boxtimes	Declaration of Inventors	(15 pages)
\boxtimes	Preliminary Amendment	(12 pages)
\boxtimes	Information Disclosure Statement	(4 pages)
	1449 Form	(2 pages)
\boxtimes	Form 609D Form	(1 page)

is being deposited with the United States Postal Service "Express Mail Post Office to Addressee; service under 37 CFR 1.10 on the date indicated above is addressed to the Mail Stop: PCT, Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450...

Margaret Turner

(Typed or printed name of person mailing paper or fee)

(Signature of person mailing paper or fee)